# 510(k) SUMMARY

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR $\ S 8 0 7 . 9 2$ .

The Assigned 5 10(k) Number is: K100682

Date: July 13, 2010

Submitted by:

Wallac Oy, subsidiary of PerkinElmer   
Mustionkatu 6   
20750 Turku, Finland

Contact Person: Primary:

Kay A. Taylor Tel: 317-418-1735 Fax: 317-536-3064

Secondary:

Katriina Suonpäã Tel: 011 358 2267 8111 Fax: 011 358 2267 8357

# Trade Name:

$\mathrm { G S P ^ { \otimes } }$ Neonatal $1 7 \alpha$ -OH-progesterone kit (3305-001U)

Common Name: Regulation:

GSP Neonatal 17-OHP kit 21 CFR 862.1395

Classification Name:

Radioimmunoassay, 17-Hydroxyprogesterone

Product Code:

JLX

Predicate Device:

AutoDELFIA® Neonatal $1 7 \alpha$ -OH-progesterone kit, 510(k) Number (K081922)

Device Description:

The GSP Neonatal $1 7 \alpha$ -OH-progesterone (17-OHP) assay is a solid phase, time-resolved fluoroimmunoassay based on the competitive reaction between europium-labeled 17- OHP and sample 17-OHP for a limited amount of binding sites on 17-OHP specific polyclonal antibodies (derived from rabbit). Danazol facilitates the release of 17-OHP from the binding proteins. A second antibody, directed against rabbit IgG, is coated to the solid phase, giving convenient separation of the antibody-bound and free antigen.

DELFIA Inducer dissociates europium ions from the labeled antigen into solution where they form highly fluorescent chelates with components of DELFIA Inducer. The fluorescence in each well is then measured. The fluorescence of each sample is inversely proportional to the concentration of 17-OHP in the sample.

Intended Use:

The GSP Neonatal $1 7 \alpha$ -OH-progesterone kit is intended for the quantitative determination of human $1 7 a$ -OHprogesterone in blood specimens dried on filter paper as an aid in screening newborns for congenital adrenal hyperplasia (CAH) using the GSPTM instrument.

Substantial Equivalence:

The GSP Neonatal $1 7 \alpha$ -OH-progesterone kit is substantially equivalent to our currently marketed AutoDELFIA Neonatal $1 7 \alpha$ -OH-progesterone kit (K081922). There are the following similarities and differences between the two kits:

Table 1. Characteristics of the two kits.   

<table><tr><td colspan="1" rowspan="1">Characteristic</td><td colspan="1" rowspan="1">GSP Neonatal 17OHP kit(New Device)</td><td colspan="1" rowspan="1">AutoDELFIA Neonatal 17OHP(Predicate Device)</td></tr><tr><td colspan="3" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1">Intended User</td><td colspan="1" rowspan="1">Adequately trained laboratorypersonnel in laboratories performingnewborn screening</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Intended Use /Indications for Use</td><td colspan="1" rowspan="1">The GSP Neonatal 17α-OH-progesterone kit is intended for thequantitative determination ofhuman 17α-OH-progesterone inblood specimens dried on filterpaper as an aid in screeningnewborns for congenital adrenalhyperplasia (CAH) using theGSPTM instrument.</td><td colspan="1" rowspan="1">The AutoDELFIA Neonatal 17α-OH-progesterone kit is intendedfor the quantitativedetermination of human 17α-OH-progesterone in bloodspecimens dried on filter paperas an aid in screening newbornsfor congenital adrenalhyperplasia (CAH) using the1235 AutoDELFIA automaticimmunoassay system.</td></tr><tr><td colspan="1" rowspan="1">Chemical Principle</td><td colspan="1" rowspan="1">Competitive reaction betweeneuropium labeled 17-OHP and sample17-OHP for a limited number ofbinding sites on 17-OHP specificpolyclonal antibodies derived fromrabbit</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Detection principle</td><td colspan="1" rowspan="1">Time-resolved fluorescence</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Specimen</td><td colspan="1" rowspan="1">Filter paper disks with a diameter ofapproximately 3.2 mm (1/8 inch)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Antibodies</td><td colspan="1" rowspan="1">Rabbit polyclonal antibodies</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Calibrator andControl Matrix</td><td colspan="1" rowspan="1">Human blood with a hematocrit of50-55% and spotted onto filter papercassettes (Whatman, no. 903)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Calibration</td><td colspan="1" rowspan="1">Calibrated using gravimetric methods</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Controls</td><td colspan="1" rowspan="1">3 levels (approx. values 17, 45 and100 ng/mL serum)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Assay Buffer</td><td colspan="1" rowspan="1">17-OHP Assay Buffer, ready for use</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Coated Plates</td><td colspan="1" rowspan="1">Anti-rabbit IgG Microtitration Strips,8 x 12 wells coated with anti-rabbitIgG (raised in goat)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Calibrators</td><td colspan="1" rowspan="1">6 levels(approx. values 0, 4, 10, 25, 75 and220 ng/mL serum)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Characteristic,continued</td><td colspan="1" rowspan="1">GSP Neonatal 17OHP kit(New Device)</td><td colspan="1" rowspan="1">AutoDELFIA Neonatal 17OHP(Predicate Device)</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="2" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Instrument</td><td colspan="1" rowspan="1">GSP Instrument</td><td colspan="1" rowspan="1">1235 AutoDELFIA Instrument</td></tr><tr><td colspan="1" rowspan="1">Dissociationsolution</td><td colspan="1" rowspan="1">DELFIA Inducer</td><td colspan="1" rowspan="1">Enhancement Solution</td></tr><tr><td colspan="1" rowspan="1">AntibodyCross-Reactionsin the Assay</td><td colspan="1" rowspan="1">17α-OH pregnenolone sulfate0.77 %11-Deoxycortisol 0.49 %17α-OH pregnenolone 0.80 %Progesterone 0.20 %21-Deoxycortisol 0.84%Deoxycorticosterone 0.01%</td><td colspan="1" rowspan="1">17α-OH pregnenolone sulfate0.78 %11-Deoxycortisol 0.62 %17α-OH pregnenolone 0.83 %Progesterone 0.37 %21-Deoxycortisol 0.91%Deoxycorticosterone 0.02%</td></tr><tr><td colspan="1" rowspan="1">Measuring RangeLinearity Range</td><td colspan="1" rowspan="1">1.4 to 220 ng/mL serum1.4-229 ng/mL serum</td><td colspan="1" rowspan="1">Same1.4-235 ng/mL serum</td></tr><tr><td colspan="1" rowspan="1">Tracer</td><td colspan="1" rowspan="1">17-OHP-Eu tracer stock solution,approximate concentration of6 nmol/L, ready-to-use</td><td colspan="1" rowspan="1">17-OHP-Eu tracer stock solution,approximate concentration of40 nmol/L, lyophilized</td></tr><tr><td colspan="1" rowspan="1">AnalyticalSensitivity / Limitof Blank,Limit of Detection</td><td colspan="1" rowspan="1">Limit of Blank0.42 ng/mL serumLimit of Detection1.4 ng/mL serum</td><td colspan="1" rowspan="1">Limit of Blank0.37 ng/mL serumLimit of Detection0.84 ng/mL serum</td></tr><tr><td colspan="1" rowspan="1">Precision (TotalVariation using afull calibrationcurve on each plate)</td><td colspan="1" rowspan="1">3.2 ng/mL serum CV% 14.95.3 ng/mL serum CV% 13.916.9 ng/mL serum CV% 11.351.6 ng/mL serum CV% 9.492.5 ng/mL serum CV% 10.9131 ng/mL serum CV% 10.1161 ng/mL serum CV% 10.9187 ng/mL serum CV% 12.0</td><td colspan="1" rowspan="1">2.12 ng/mL serum CV% 13.04.69 ng/mL serum CV% 9.87.52 ng/mL serum CV% 14.827.0 ng/mL serum CV% 8.354.4 ng/mL serum CV% 9.2109 ng/mL serumCV% 10.8182 ng/mL serumCV% 9.1</td></tr><tr><td colspan="1" rowspan="1">Expected Values inNewborns (perbirth weight and95th percentile)</td><td colspan="1" rowspan="1">&lt; 1250 g 94.1 ng/mL serum1250-2249 g47.5 ng/mL serum≥ 2250 g13.8 ng/mL serum</td><td colspan="1" rowspan="1">Site 1:&lt; 1250 g73.6 ng/mL serum1250-2249 g40.8 ng/mL serum≥ 2250 g20.9 ng/mL serumSite 2:&lt; 1250 g95.0 ng/mL serum1250-2249 g 668.6 ng/mL serum≥ 2250 g 28.3 ng/mL serum</td></tr><tr><td colspan="1" rowspan="1">EndogenousInterferences</td><td colspan="1" rowspan="1">Icteric (unconjugated bilirubin ≤342 µmol/L, equivalent to 20mg/dL and conjugated bilirubin ≤237 µmol/L, equivalent to 20mg/dL),Hemolytic (additional hemoglobin≤ 0.5 g/dL),Lipemic (Intralipid ≤ 3000 mg/dLat 17OHP levels of 30 and 70ng/mL and Intralipid ≤ 750 mg/dLat 17OHP levels of 150 ng/mL)specimens do not interfere with theassay.</td><td colspan="1" rowspan="1">Icteric (unconjugated bilirubin ≤342 μmol/L, equivalent to 20mg/dL and conjugated bilirubin≤ 237 µmol/L, equivalent to 20mg/dL),Hemolytic (additionalhemoglobin ≤ 0.5 g/dL).Lipemic (Intralipid ≤ 3000mg/dL) specimens do notinterfere with the assay.</td></tr><tr><td colspan="1" rowspan="1">MethodComparison</td><td colspan="2" rowspan="1">The GSP kit (y) was compared to the AutoDELFIA kit (x) with 2567samples over a range of 1.4 - 220 ng/mL serum. Y= 0.97x + 0.27; r = 0.96;</td></tr></table>

# Screening Efficacy:

The GSP kit and the predicate device were compared in one newborn screening laboratory using retrospective archived specimens and leftover samples from specimens submitted for routine screening. A total of 23 known CAH cases were included in the 2589 samples evaluated. The results are presented in tables 2 -7 using the $9 0 ^ { \mathfrak { h } }$ , $9 5 ^ { \mathfrak { t h } }$ and $9 9 ^ { \mathfrak { h } }$ percentile cut-offs.

Table 1 Distribution of specimens into GSP and AutoDELFIA test results categories when using the highest $90 \%$ percentile cutoff. The agreement- $\% 3$ with $9 5 \%$ CIs are also presented $( \geq 2 5 0 0 \mathrm { g } )$ .   

<table><tr><td rowspan=1 colspan=1>90% cutoff</td><td rowspan=1 colspan=3>AutoDELFIA</td></tr><tr><td rowspan=1 colspan=1>GSP</td><td rowspan=1 colspan=1>Test Positive</td><td rowspan=1 colspan=1>Test Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Test Positive</td><td rowspan=1 colspan=1>165</td><td rowspan=1 colspan=1>39</td><td rowspan=1 colspan=1>F204</td></tr><tr><td rowspan=1 colspan=1>Test Negative</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>1602</td><td rowspan=1 colspan=1>1638</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>201</td><td rowspan=1 colspan=1>1641</td><td rowspan=1 colspan=1>1842</td></tr></table>

Overall percent agreement $= ( 1 6 5 + 1 6 0 2 ) / 1 8 4 2 ^ { * } 1 0 0 \% = 9 5 . 9 \%$ $\mathrm { C I } 9 4 . 9 \% 9 6 . 8 \%$ Positive percent agreement $= ( 1 6 5 / 2 0 1 ) ^ { \ast } 1 0 0 \% = 8 2 . 1 \% ( \mathrm { C }$ $( \mathrm { C l } 7 6 . 1 \% 8 7 . 1 \% )$ EMP Negative percent agreement $= ( 1 6 0 2 / 1 6 4 1 ) ^ { * } 1 0 0 \% = 9 7 . 6 \% ( \mathrm { C l } 9 6 . 8 \% 9 8 . 3 \% )$

Table 2 Distribution of specimens into GSP and AutoDELFIA test results categories when using the highest $9 0 \%$ percentile cutoff. The agreement- $\cdot \% 3$ with $9 5 \%$ CIs are also presented $( 1 2 5 0 \mathrm { g } { - 2 2 4 9 \mathrm { g } } )$ .   

<table><tr><td rowspan=1 colspan=1>90% cutoff</td><td rowspan=1 colspan=3>AutoDELFIA</td></tr><tr><td rowspan=1 colspan=1>GSP</td><td rowspan=1 colspan=1>Test Positive</td><td rowspan=1 colspan=1>Test Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Test Positive</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>45</td></tr><tr><td rowspan=1 colspan=1>Test Negative</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>391</td><td rowspan=1 colspan=1>394</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>394</td><td rowspan=1 colspan=1>439</td></tr></table>

Overall percent agreement $= ( 4 2 + 3 9 1 ) / ( 4 3 9 ) ^ { \ast } 1 0 0 \% = 9 8 . 6 \%$ $\operatorname { C I } 9 7 . 0 \% 9 9 . 5 \% )$ Positive percent agreement $= ( 4 2 / 4 5 ) ^ { \ast } 1 0 0 \% = 9 3 . 3 \%$ (CI 81.7%-98.6%) Negative percent agreement $: = ( 3 9 1 / 3 9 4 ) ^ { \ast } 1 0 0 \% = 9 9 . 2 \%$ (Cl 97.8%-99.8%)

Table 3 Distribution of specimens into GSP and AutoDELFIA test results categories when using the highest $90 \%$ percentile cutoff. The agreement- $\% 3$ with $9 5 \%$ CIs are also presented $( < 1 2 5 0 \underline { { \bf g } } )$   

<table><tr><td rowspan=1 colspan=1>90% cutoff</td><td rowspan=1 colspan=3>AutoDELFIA</td></tr><tr><td rowspan=1 colspan=1>GSP</td><td rowspan=1 colspan=1>Test Positive</td><td rowspan=1 colspan=1>Test Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Test Positive</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>31</td></tr><tr><td rowspan=1 colspan=1>Test Negative</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>271</td><td rowspan=1 colspan=1>277</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>277</td><td rowspan=1 colspan=1>308</td></tr></table>

Overall percent agreement $\tan { \iota = ( 2 5 + 2 7 1 ) / ( 3 0 8 ) ^ { \ast } 1 0 0 \% } = 9 6 . 1 \% ( \mathrm { C l } 9 3 . 3 \% 9 9 9 8 . 0 \% )$ Positive percent agreement $: = ( 2 5 / 3 1 ) ^ { * } 1 0 0 \% = 8 0 . 6 \%$ (CI 62.5%-92.5%) Negative percent agreement $: = ( 2 7 1 / 2 7 7 ) ^ { \ast } 1 0 0 \% = 9 7 . 8 \%$ $\mathsf { C I 9 5 . 3 \% 9 9 . 2 \% }$

Table 4 Distribution of specimens into GSP and AutoDELFIA test results categories when using the highest $9 5 \%$ percentile cutoff. The agreement- $\% 3$ with $9 5 \%$ CIs are also presented $\underline { { ( \geq 2 5 0 0 \mathrm { g } ) } }$ .   

<table><tr><td rowspan=1 colspan=1>95% cutoff</td><td rowspan=1 colspan=3>AutoDELFIA</td></tr><tr><td rowspan=1 colspan=1>GSP</td><td rowspan=1 colspan=1>Test Positive</td><td rowspan=1 colspan=1>Test Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Test Positive</td><td rowspan=1 colspan=1>95</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>111</td></tr><tr><td rowspan=1 colspan=1>Test Negative</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>1713</td><td rowspan=1 colspan=1>1731</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>113</td><td rowspan=1 colspan=1>1729</td><td rowspan=1 colspan=1>1842</td></tr></table>

Overall percent agreement $= ( 9 5 + 1 7 1 3 ) / 1 8 4 2 ^ { * } 1 0 0 \% = 9 8 . 2 \%$ $\mathrm { C I } 9 7 . 4 \% 9 8 . 7 \% )$ EPY Positive percent agreement $= ( 9 5 / 1 1 3 ) ^ { \ast } 1 0 0 \% = 8 4 . 1 \% ( \mathrm { C }$ $\mathrm { ( C I } 7 6 . 0 \% . 9 0 . 3 \% $ Negative percent agreement $= ( 1 7 1 3 / 1 7 2 9 ) ^ { \ast } 1 0 0 \% = 9 9 . 1 \%$ l $\mathrm { C I 9 8 . 5 \% - 9 9 . 5 \% }$

Table 5 Distribution of specimens into GSP and AutoDELFIA test results categories when using the highest $9 5 \%$ percentile cutoff. The agreement- $\bullet \prime _ { 0 } ; s$ with $9 5 \%$ CIs are also presented $( 1 2 5 0 \mathrm { g } { - 2 2 4 9 \mathrm { g } } )$   

<table><tr><td rowspan=1 colspan=1>95% cutoff</td><td rowspan=1 colspan=3>AutoDELFIA</td></tr><tr><td rowspan=1 colspan=1>GSP</td><td rowspan=1 colspan=1>Test Positive</td><td rowspan=1 colspan=1>Test Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Test Positive</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>23</td></tr><tr><td rowspan=1 colspan=1>Test Negative</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>413</td><td rowspan=1 colspan=1>416</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>416</td><td rowspan=1 colspan=1>439</td></tr></table>

Overall percent agreement $= ( 2 0 + 4 1 3 ) / 4 3 9 * 1 0 0 \% = 9 8 . 6 \% ( ($ $( \mathrm { C l } 9 7 . 0 \% 9 9 . 5 \% )$ Positive percent agreement $= ( 2 0 / 2 3 ) ^ { \ast } 1 0 0 \% = 8 7 . 0 \%$ $\operatorname { C l } 6 6 . 4 \% 9 7 . 2 \% )$ . Negative percent agreement $= ( 4 1 3 / 4 1 6 ) ^ { \ast } 1 0 0 \% = 9 9 . 3 \%$ $\yen 1923,456,792$ )

Table 6 Distribution of specimens into GSP and AutoDELFIA test results categories when using the highest $9 5 \%$ percentile cutoff. The agreement $\cdot \% : s$ with $9 5 \%$ CIs are also presented $( < 1 2 5 0 \mathrm { g } )$   

<table><tr><td rowspan=1 colspan=1>95% cutoff</td><td rowspan=1 colspan=3>AutoDELFIA</td></tr><tr><td rowspan=1 colspan=1>GSP</td><td rowspan=1 colspan=1>Test Positive</td><td rowspan=1 colspan=1>Test Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Test Positive</td><td rowspan=1 colspan=1>,    11</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>16</td></tr><tr><td rowspan=1 colspan=1>Test Negative</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>287</td><td rowspan=1 colspan=1>292</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>292</td><td rowspan=1 colspan=1>308</td></tr></table>

Overall percent agreement $= ( 1 1 + 2 8 7 ) / 3 0 8 ^ { \ast } 1 0 0 \% = 9 6 . 8 \% 1$ $( \mathrm { C I } 9 4 . 1 \% 9 8 . 4 \% )$ Positive percent agreement $\approx ( 1 1 / 1 6 ) ^ { * } 1 0 0 \% = 6 8 . 8 \%$ $( \mathsf { C l } 4 1 . 3 \% 8 9 . 0 \% )$ . Negative percent agreement $= ( 2 8 7 / 2 9 2 ) ^ { * } 1 0 0 \% = 9 8 . 3 \%$ $( \mathsf { C l 9 6 . 0 \% 9 9 . 4 \% } )$

Table 7 Distribution of specimens into GSP and AutoDELFIA test results categories when using the highest $9 9 \%$ percentile cutoff. The agreement- $\% 3$ with $9 5 \%$ CIs are also presented $\underline { { ( 2 2 5 0 0 \mathrm { g } ) } }$ .   

<table><tr><td rowspan=1 colspan=1>99% cutoff</td><td rowspan=1 colspan=3>AutoDELFIA</td></tr><tr><td rowspan=1 colspan=1>GSP</td><td rowspan=1 colspan=1>Test Positive</td><td rowspan=1 colspan=1>Test Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Test Positive</td><td rowspan=1 colspan=1>39</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>41</td></tr><tr><td rowspan=1 colspan=1>Test Negative</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1800</td><td rowspan=1 colspan=1>1801</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>1802</td><td rowspan=1 colspan=1>1842</td></tr></table>

Overall percent agreement $= ( 3 9 + 1 8 0 0 ) / 1 8 4 2 * 1 0 0 \% = 9 9 . 8 \%$ $\approx 1 9 9 . 5 \% . 1 0 0 \% ,$ Positive percent agreement $= ( 3 9 / 4 0 ) ^ { \ast } 1 0 0 \% = 9 7 . 5 \%$ — $\operatorname { C l } 8 6 . 8 \% 9 \% 9 \%$ Negative percent agreemen $\mathfrak { t } = ( 1 8 0 0 / 1 8 0 2 ) ^ { \ast } 1 0 0 \% = 9 9 . 9 \%$ $\mathbf { \tilde { C } I 9 9 . 6 \% 1 0 0 \% }$ .

Table 8 Distribution of specimens into GSP and AutoDELFIA test results categories when using the highest $9 9 \%$ percentile cutoff. The agreement- $\cdot \% 3$ with $9 5 \%$ Cls are also presented $1 2 5 0 \mathrm { g } { - 2 2 4 9 \mathrm { g } } )$ .   

<table><tr><td rowspan=1 colspan=1>99% cutoff</td><td rowspan=1 colspan=3>AutoDELFIA</td></tr><tr><td rowspan=1 colspan=1>GSP</td><td rowspan=1 colspan=1>Test Positive</td><td rowspan=1 colspan=1>Test Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Test Positive</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>6</td></tr><tr><td rowspan=1 colspan=1>Test Negative</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>429</td><td rowspan=1 colspan=1>433</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>433</td><td rowspan=1 colspan=1>439</td></tr></table>

Overall percent agreement $= ( 2 + 4 2 9 ) / 4 3 9 ^ { \ast } 1 0 0 \% = 9 8 . 2 \% ( \mathrm { C I ~ 9 6 . 4 \% 9 9 . 2 \% } )$ Positive percent agreement $= ( 2 / 6 ) ^ { * } 1 0 0 \% = 3 3 . 3 \%$ $\yen 123,456,77,78$ Negative percent agreemen $\mathrm { t } = ( 4 2 9 / 4 3 3 ) ^ { \ast } 1 0 0 \% = 9 9 . 1 \%$ $\mathrm { ( C I ~ 9 7 . 7 \% 9 9 . 7 \% ) }$

Table 1 Distribution of specimens into GSP and AutoDELFIA test results categories when using the highest $9 9 \%$ percentile cutoff. The agreement- $\% 3$ with $9 5 \%$ CIs are also presented $( < 1 2 5 0 \mathrm { g } )$ .   

<table><tr><td rowspan=1 colspan=1>99% cutoff</td><td rowspan=1 colspan=3>AutoDELFIA</td></tr><tr><td rowspan=1 colspan=1>GSP</td><td rowspan=1 colspan=1>Test Positive</td><td rowspan=1 colspan=1>Test Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Test Positive</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td></tr><tr><td rowspan=1 colspan=1>Test Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>304</td><td rowspan=1 colspan=1>304</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>′4</td><td rowspan=1 colspan=1>304</td><td rowspan=1 colspan=1>308</td></tr></table>

Overall percent agreement $= ( 4 + 3 0 4 ) / 3 0 8 ^ { \ast } 1 0 0 \% = 1 0 0 \% ( \mathrm { C I } 9 8 . 8 \% 1$ Positive percent agreement $= ( 4 / 4 ) ^ { \ast } 1 0 0 \% = 1 0 0 \%$ cYanmaGentaYYellowb $\left( \mathrm { C 1 } 3 9 . 8 \% 1 0 0 \% \right)$ Negative percent agreement $: = ( 3 0 4 / 3 0 4 ) ^ { \ast } 1 0 0 \% = 1 0 0 \%$ $( \mathbf { C } ] 9 8 . 8 \% 1 0 0 \% )$

Wallac Oy   
Subsidiary of PerkinElmer   
c/o Kay A. Taylor   
Director, Regulatory and Clinical Affairs   
8275 Carloway Road   
Indianapolis, IN 46236

Re: k100682 Trade/Device Name: GSP Neonatal $1 7 a$ -OH-progesterone kit (3305-001U) Regulation Number: 21 CFR $\ S 8 6 2 . 1 3 9 5$ EY Regulation Name: 17-Hydroxyprogesterone Test System Regulatory Class: Class I; meets limitations of exemptions under 21 CFR $\ S 8 6 2 . 9$ (c)(2) Product Code: JLX Dated: June 3, 2010 Received: June 7, 2010

Dear Kay A. Taylor:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 1, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or ( 301 ) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Cc

Courtny C. Harper, Ph.D.   
Directr   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

Enclosure

# Indications for Use Form

510(k) Number (if known): k100682

Device Name: $\mathrm { G S P } ^ { \mathfrak { B } }$ Neonatal $1 7 a$ OH-progterone kit (305-001U)

Indications for Use:

The GSP Neonatal $1 7 \alpha$ -OH-progesterone kit is intended for the quantitative determination of human $1 7 \alpha$ -OH-progesterone in blood specimens dried on filter paper as an aid in screening newborns for congenital adrenal hyperplasia (CAH) using the GSPTM instrument.

Concurrence of CDRH, Offce of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

![](images/f6fe77b9b10bc190b3e1111199075d6f5f523b0ad167b458c188d06833841bc5.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety